| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486176 | Vaccine | 2018 | 6 Pages |
Abstract
The maximum impact of pneumococcal conjugate vaccination has been attained and signs of a rebound are apparent. Sustained surveillance for IPD in children is warranted to assess whether these trends will continue. There may be a need for vaccines using antigens common to all serotypes.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Raphael Weinberger, Rüdiger von Kries, Mark van der Linden, Thorsten Rieck, Anette Siedler, Gerhard Falkenhorst,